We are honoured to celebrate another incredible year supporting and partnering with our vibrant life sciences community. The people and organizations who comprise our ecosystem inspire us every day. This festive season, we send you our best wishes for a restful and restorative break with family and friends. Happy holidays, and may you have a wonderful and prosperous New Year.

– Wendy, Ryan, Lisa, Johanna, Claire, and William

AbCellera and AbbVie Partner to Advance New Antibody Therapies

AbCellera announced that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc.The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications. Under the terms of the agreement, AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products...READ MORE

Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer

Alpha-9 Theranostics Inc., a clinical stage company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer, announced an oversubscribed $75 million Series B financing. The round was led by Nextech Invest, with participation from Frazier Life Sciences, Samsara BioCapital and Quark Venture in addition to existing investors Longitude Capital and BVF Partners...READ MORE

UBC Scientists Identify Broadly-Effective, Infection-Halting Compound

Researchers at UBC’s Life Sciences Institute have identified a compound that shows early promise at halting infections from a range of coronaviruses, including all variants of SARS-CoV-2 and the common cold.

The findings, published this week in Molecular Biomedicine, reveal a potential path toward antiviral treatments that could be used against many different pathogens...READ MORE

Gilead Sciences Again Named to Dow Jones Sustainability World Index

Gilead Sciences announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead’s sustainability performance and highlights the company’s longstanding sustainable business practices and transparency on environmental, social and governance issues...READ MORE

LIFE Prospectus Exemption Offers Greater Access to Capital and Broader Retail Investment Choice

After significant collaboration within the Canadian Securities Administrators and following a comprehensive public consultation process, Canada now has a new prospectus exemption aimed at providing a more efficient way for listed companies to raise capital. The Listed Issuer Financing Exemption will reduce costs for companies raising smaller amounts of capital through the public markets. It will also allow listed companies greater access to retail investors and thereby also provide retail investors with a broader choice of investments...READ MORE

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces the Company has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022...READ MORE

Optimize Your Time and Investment by Downloading a Networking Info App for the 41st Annual JP Morgan Health Care Conference

Novateur Ventures, a leading global life sciences advisory firm and Biotechnology Innovation Organization (BIO), the world’s largest advocacy association for biosciences, research and academic institutions, launched an industry networking information app, Event Guide to JPM 2023, which provides listings for an anticipated >200 satellite networking events taking place during the 41st Annual J.P. Morgan Health Care Conference on January 9-12, 2023, in San Francisco, CA...READ MORE

New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented at 2022 SABCS

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, presented new clinical data for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor degrader, in patients with heavily pretreated HER2-positive hormone-receptor positive metastatic breast cancer...READ MORE

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced that its research division has submitted a clinical trial application to Health Canada to begin a new experiential training study that will enable practitioners training to provide Psilocybin-Assisted Therapy (PAT) the ability to experience and observe psilocybin sessions to further their understanding and PAT education...READ MORE

Phase III Trial Demonstrated Jardiance® is the First SGLT2 Inhibitor to Show Statistically Significant Reduction in Blood Sugar Levels in Children and Adolescents with Type 2 Diabetes

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes. When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012). The results were presented at the International Diabetes Federation World Diabetes congress 2022, Boehringer Ingelheim and Eli Lilly and Company announced...READ MORE

Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis

Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced that it has completed enrollment, randomization and dosing of the last patient, in its Phase 2 trial that is evaluating the efficacy and safety of EP-104 for the treatment of osteoarthritis (“OA”) of the knee...READ MORE

Response Biomedical’s RAMP COVID-19 Antigen Test gets Health Canada Approval

Response Biomedical Corp., a global provider of acute care diagnostic testing solutions, is announcing that Health Canada has granted the RAMP® COVID-19 Antigen Test authorization to commercialize under the Emergency Use Interim Order. The Health Canada authorization allows Response to market and sell the RAMP® COVID-19 Antigen Test to countries that recognize Health Canada authorization...READ MORE

InBC Announces First Investments Into Venture Funds to Support Entrepreneurs Driving Climate Action, Reconciliation and Innovation

InBC Investment Corp. announces its first investments into venture capital funds aligned with its triple bottom line mandate to consider people, planet and profit. InBC is a provincial Crown corporation with $500 million to invest in venture capital funds and growing small and medium-sized businesses to benefit British Columbians. InBC has invested into three B.C.-based funds — Evok Innovations, Raven Indigenous Capital Partners and Yaletown Partners — to drive climate action, reconciliation and innovation alongside financial returns. Investing in venture capital funds, pooled investments providing financing to emerging businesses, is the first step in the launch of InBC’s overall investment strategy...READ MORE

Government of Canada Invests in MEDTEQ+ to Fund Groundbreaking Technologies That Will Benefit Canada’s Seniors and Their Families

The Honourable Jean-Yves Duclos, Minister of Health, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced an investment of $47 million through the Strategic Innovation Fund to support MEDTEQ+’s $154 million envisAGE Network, established with network co-lead AGE-WELL. This contribution will bring together industry, health experts and investors to launch up to 100 projects to scale up and commercialize technologies, developed by small and medium-sized enterprises, that are ready for national and global market adoption...READ MORE

Research Associate – Formulation

The Research Associate will perform research related to the development of LNP formulations for nucleic acid delivery for in vivo and in vitro applications. This will include characterization of biophysical attributes, optimization of formulation processes at various scales and contribution to the understanding of the mechanisms of action. In addition, the Research Associate, independently and as part of the team, is expected to analyze and interpret data. The Research Associate is required to keep up to date and accurate laboratory notes and data files as well as regularly prepare internal reports of their work. The Research Associate is expected to maintain familiarity with the scientific knowledge and advancements within the Company’s strategic sphere.

LEARN MORE

Technician, Process Development

Avivo Biomedical are seeking a highly motivated Technician to join the Process Development and Analytic team at Avivo. In this capacity, the Technician will support the development of upstream and downstream processes, as well as impurity assay development to support the ongoing development of our bacterial-produced enzyme-based product. These activities will involve a combination of protein biochemistry, enzymology and molecular biology. An ideal candidate must be able to take initiative in problem solving, prioritize assignments, work efficiently under time constraints, and work within teams and with minimum supervision.

LEARN MORE

Marketing Associate

Response Biomedical are seeking a dynamic Marketing Associate who is self-motivated and enjoys working in a fast paced environment. This position is responsible for developing and implementing marketing/ advertising activities and create strategies to promote company’s product, services, and brand, accountable for digital channels to raise brand awareness and generate leads, for the core purpose of improving patient outcomes and saving lives globally. Key responsibilities include handling digital marketing, outbound marketing, lead management, and corporate marketing.

LEARN MORE

Medtech Canada is the national association representing Canada's innovative medical technology industry.

Representing approximately 100 medtech companies (ranging from Canadian-owned to multinationals), Medtech Canada works closely with the federal and provincial-territorial governments, health professionals, patients and other stakeholders to deliver a patient-centred, safe, accessible, innovative and sustainable, universal healthcare system supported by the use of medical technology.

Visit Website

PharmaBioSource is a Life Sciences advisory and consulting firm specializing in global facilities and product transactions for pharmaceutical, biotech, and Life Sciences companies.

They also consult with healthcare investors to support Life Sciences investment due diligence and risk analysis. PharmaBioSource offers an extensive collection of expert pharma advisory services and solutions that are designed to help your company make strategic decisions and improve how you do business.

Visit Website